BEAT News & Events

HeartBeam announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam's patented ECG platform, which captures the heart's electrical activity from 3 non-coplanar dimensions. The company said, "Under the collaboration, HeartBeam's in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership."

HeartBeam announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia.

HeartBeam announced a commercial partnership with ClearCardio. In addition to serving as HeartBeam's first commercial customer, ClearCardio also plans to make an investment in HeartBeam. The partnership includes an initial staged rollout and plans for broader expansion to thousands of members across multiple U.S. geographies. ClearCardio will incorporate HeartBeam's synthesized 12-lead ECG technology into the program for arrhythmia assessment. The initial agreement with ClearCardio is structured as a letter of intent, outlining the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase, HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.